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Abstract The first autosomal dominant missense mutation
(G272A) reported within the human GLUT1 gene and shared
by three affected family members was investigated in respect to
functional consequences. Substitution of glycine-91 by site-
directed mutagenesis with either aspartate or alanine resulted
in a significant decrease in transport activity of GLUT1
expressed in Xenopus oocytes. Expression of mutant transporters
was confirmed by immunoblot, 2-deoxy-glucose uptake and
confocal laser microscopy. The data agree with 3-O-methyl-
glucose uptake into patient erythrocytes and indicate that the
loss of glycine rather than a hydrophilic side chain (Gly91Asp)
defines the functional consequences of this mutation. ß 2001
Published by Elsevier Science B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Transport of D-glucose across the blood^brain barrier
(BBB) is mediated exclusively by the sodium-independent, fa-
cilitative transporter GLUT1 [1^3]. Focal seizures or brain
injury have been shown to locally a¡ect GLUT1-mediated
glucose transport into the brain [4^7]. In contrast, a primary
GLUT1 defect has recently been identi¢ed and termed
GLUT1 De¢ciency Syndrome or De Vivo Disease. This con-
dition results in seizures, developmental delay and complex
motor disorders in childhood [8^10]. Several heterozygous in
vivo mutations have been reported in GLUT1 De¢ciency Syn-
drome, indicating an autosomal dominant disorder resulting
from GLUT1 haploinsu⁄ciency [11^13]. The erythrocyte
GLUT1 protein is identical in molecular weight and antigenic
properties to the GLUT1 protein in brain capillary endothe-
lial cells [14]. Analyses of the GLUT1 protein in patients’
erythrocytes showed impaired GLUT1 function, whereas
GLUT1 immunoreactivity was reduced [11] or normal [10,13].
We recently reported a father and two children from sepa-
rate marriages sharing a heterozygous missense mutation
(G272A) in exon 3 of the human GLUT1 gene, and present-
ing with clinical features of GLUT1 De¢ciency Syndrome
[13]. In all three individuals GLUT1 immunoreactivity of er-
ythrocyte membranes was normal, but 3-O-methyl-D-glucose
(3OMG) uptake into erythrocytes was signi¢cantly reduced,
suggesting a quantitatively normal, but functionally impaired
GLUT1 protein at the cell membrane. The predicted amino
acid change (Gly91Asp) was located within an Arg-X-Gly-
Arg-Arg motif between transmembrane segments 2 and 3
that is highly conserved among transporters of the major fa-
cilitator superfamily [15] and might be involved in salt-bridg-
ing between helices, in maintaining conformational stability,
or in serving as a cytoplasmic anchor point for the protein
[16^19]. To evaluate pathogenicity, we substituted glycine-91
with either aspartate or alanine by site-directed mutagenesis in
the human GLUT1 cDNA and investigated the functional
consequences using the Xenopus oocyte expression system.
Assessment of transport rates in erythrocytes or Xenopus oo-
cytes indicates that both mutations signi¢cantly reduce the
catalytic activity of GLUT1.
2. Materials and methods
2.1. Mutagenesis
A 1523-bp BamHI/BstYI fragment of human GLUT1 cDNA de-
rived from pSPGT [15] was subcloned into a BglII site of the Xenopus
oocyte expression vector pSP64T [20]. Site-directed mutagenesis was
carried out by polymerase chain reaction using the ‘QuickChange1
Site-Directed Mutagenesis Kit’ to change glycine-91 to aspartate (the
native human mutation) or alanine. The mutants were con¢rmed by
restriction fragment analysis and ¢nally by DNA sequencing with a
£uorescence DNA sequencer (ABI PRISM) connected to a Macintosh
computer.
2.2. cRNA synthesis
In vitro synthesis of capped cRNA was conducted according to a
standard protocol provided by Ambion (mMESSAGE mMACHINE,
Ambion, Austin, USA). The amount of transcribed RNA was calcu-
lated by incorporated [35S]thioUTP. Its concentration was adjusted to
0.25^0.5 mg/ml. Collection, defolliculation and culture of Xenopus
oocytes were carried out as described previously [21,22].
2.3. Immunoblot and confocal laser microscopy
Thirty Xenopus oocytes injected with water (sham), wild-type
GLUT1 or the indicated mutant cRNAs were selected for preparation
of total membrane fractions, modi¢ed from Geering et al. [26]. The
membrane fractions from the ¢nal 165 000Ug spin were kept at
380‡C until Western blot analysis. 8 Wg of protein were separated
by sodium dodecyl sulphate (SDS)^polyacrylamide gel electrophoresis
(PAGE) and electroblotted onto a nitrocellulose membrane by stan-
dard protocols. Membranes were stained with Ponceau S to con¢rm
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the uniform e⁄ciency of transfer. The GLUT1 protein was identi¢ed
using a polyclonal rabbit GLUT1 antibody (Cymbus Biotechnology,
Chandlers Ford, Hants, UK), raised against the C-terminus of
GLUT1. Primary antibodies were detected by enhanced chemilumi-
nescence (Amersham Life Science, Arlington Heights, IL, USA). The
preparation of oocytes for confocal laser microscopy followed a pro-
tocol described previously [25]. The £uorescence of three oocytes per
group was scanned from the cut surface to a depth of 10 Wm using the
LSM 510 confocal laser scanning microscope (Carl Zeiss, Jena, Ger-
many). The relative intensity of the plasma membrane £uorescence
was divided by the average relative intensity of the cytoplasmic £uo-
rescence. The £uorescence of the cytoplasm was scanned along a line
of 40 Wm from the periphery to the cell interior and was normalised to
the area of the plasma membrane £uorescence. For each group, 3^4
separate oocytes per group were included in the confocal imaging.
2.4. Zero-trans 3OMG in£ux into erythrocytes
Zero-trans 3OMG in£ux into erythrocytes was performed as de-
scribed [27]. Brie£y, blood specimens were collected in citrate^dex-
trose^phosphate solution, immediately put on wet ice, and processed
within 48 h. All procedures were performed at 4‡C. Blood samples
were washed three times in phosphate-bu¡ered saline (PBS) and ali-
quots were incubated at increasing concentrations of [14C]3OMG.
Uptake was terminated, the aliquots washed twice, lysed, bleached
and counted in a Scintillation Counter (Tricarb 2300, Canberra Pack-
ard, Germany).
2.5. Zero-trans 2-deoxy-D-glucose (2DOG) in£ux into Xenopus oocytes
The accumulation of tritium-labelled 2DOG (50 WM, 1 WCi/0.5 ml
transport assay) in single Xenopus oocytes was assessed for 30 min at
room temperature in a transport assay using 20^30 oocytes/datapoint.
Kinetic data was determined over a substrate concentration ranging
Fig. 1. The amino-terminus and helices 1^3 are shown within the
conformational model for GLUT1 in the membrane as proposed by
Mueckler et al. [2]. The 89Arg-X-Gly-Arg-93Arg motif within the in-
tra-cellular loops joining transmembrane segments 2^3 carrying the
mutation is shown in black with the nucleotide (G272A) and the
amino acid (Gly91Asp) exchange indicated (adapted from [9]).
C
Fig. 2. Comparison of membrane glucose transporter levels by im-
munoblotting or confocal laser microscopy. A: Western blot analy-
ses was conducted for Xenopus oocyte membranes expressing water-
injected oocytes (sham) and oocytes expressing wild-type GLUT1 or
the 91GlyCAsp and 91GlyCAla GLUT1 mutants. Total membrane
fractions were isolated as described in Section 2. Protein concentra-
tion was determined and 8 Wg of protein submitted to SDS^PAGE,
transferred to a polyvinylidene £uoride microporous membrane, and
probed with antibodies speci¢c for the GLUT1 carboxy-terminus.
B: Confocal laser scanning microscopy was performed for Xenopus
oocytes expressing water-injected oocytes (sham) and oocytes ex-
pressing wild-type GLUT1 or the 91GlyCAsp and 91GlyCAla
GLUT1 mutants. Oocytes were randomly selected, ¢xed and cut
along the equator into two halves. An anti-GLUT1 antipeptide anti-
body (AK 1462; 20 Wg/ml) was used as ¢rst antibody, the second
antibody was a £uorescein isothiocyanate-conjugated goat anti-rab-
bit IgG (diluted 1:300 in PBS plus 2% horse serum). Confocal im-
ages from three to four oocytes per group were obtained by scan-
ning the £uorescence from the cut surface to a depth of 10 Wm.
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from 0.5 to 25 mmol/l (i.e. 0.5, 0.7, 1.0, 2.0 and 25 mmol/l). Transport
was stopped by the addition of 4‡C PBS containing 0.1 mM phloretin
followed by three additional washes to remove adhering radioactivity.
Oocytes were dissolved in 1% SDS before radioactivity was deter-
mined by a liquid scintillation spectrophotometer [23^25].
3. Results
The G272A mutation identi¢ed in exon 3 of the human
GLUT1 gene resulted in a Gly91Asp substitution within the
highly conserved 89Arg-X-Gly-Arg-93Arg motif that is part of
the ¢rst intra-cellular loop joining transmembrane segments 2
and 3 (Fig. 1).
Expression of wild-type or mutant GLUT1 transporters in
total membrane fractions of Xenopus oocytes was investigated
by Western blotting. Immunoreactivity was comparably in-
tense for both the native and the mutant transporters (Fig.
2A). Confocal imaging focused on immunoreactivity of the
transporter proteins in the plasma membrane. Mutant trans-
porters were present at the plasma membrane at levels com-
parable with wild-type GLUT1 (Fig. 2B). The ratio of plasma
membrane to cytoplasm £uorescence intensity was 1.21 for
sham, 6.75 þ 1.20 for wild-type GLUT1 (n = 4), 6.62 þ 1.22
for the G91D mutant (n = 3) and 7.00 þ 0.86 for the G91A
mutant (n = 3). For details, see Section 2.
Uptake values previously reported [13] in patient I:2 and
II:5 (57%) and a control subject (89%), based on data of 70
normal controls [27], are shown in Fig. 3A (numbering of
patients according to [13]). To evaluate saturation kinetics,
zero-trans 3OMG in£ux was determined as a function of sub-
strate concentration in erythrocytes in all patients and a con-
trol (Fig. 3B,C). Maximal transport velocity (Vmax) was sig-
ni¢cantly reduced in all three patients compared to the intra-
assay control, whereas no di¡erences were observed for the
apparent Michaelis constant (Km) (Table 1).
Using the pSP64T-GLUT1 construct glycine-91 in the hu-
man GLUT1 cDNA was substituted by site-directed muta-
genesis either with aspartate, the in vivo mutation, or alanine.
Following expression of the mutant transporters in Xenopus
oocytes 2DOG uptake rates were assessed and compared to
those from water-injected and wild-type GLUT1-expressing
oocytes. Both the aspartate and alanine replacement of gly-
cine-91 resulted in a decrease in transport activity into Xen-
opus oocytes by about 40% (Fig. 3D). In Xenopus oocytes, the
G91D and the G91A mutants showed signi¢cant reduction in
both Vmax and apparent Km values compared to Xenopus oo-
cytes expressing wild-type GLUT1 (Fig. 3E and Table 1).
4. Discussion
GLUT1 De¢ciency Syndrome has been increasingly recog-
nised as a distinct clinical entity resulting in seizures, devel-
opmental delay and complex motor disorders. As such, it
represents the ¢rst known defect of transport across the
BBB [8^10,28]. It can be treated e¡ectively by means of a
ketogenic diet, as ketones readily enter the brain by an inde-
pendent, active transport system and serve as an alternative
fuel for cerebral energy metabolism [10,29]. Mutational anal-
yses identi¢ed a variety of private, heterozygous mutations in
the GLUT1 gene in patients with GLUT1 De¢ciency Syn-
drome [10^13]. Mutations were randomly located in various
exons. In contrast to hemizygosity or non-sense mutations,
the pathogenicity of missense mutations is not always clear.
Mueckler et al. [38] showed that a highly conservative GLUT2
Val197Ile substitution, identi¢ed in a patient with non-insulin-
dependent diabetes and expressed in Xenopus oocytes, abol-
ished transport activity. This observation represented the ¢rst
known dysfunctional mutation in a human facilitative glucose
transporter protein [30], but the expectation that this muta-
tion may be causally involved in the pathogenesis of non-in-
Fig. 3.
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sulin-dependent diabetes was not con¢rmed in subsequent
studies [31,32]. Expressing a mutant gene in Xenopus oocytes
has since been shown to be an e¡ective strategy to inves-
tigate the functional and structural consequences of muta-
tions identi¢ed by molecular analyses (recent contributions:
[25,33]).
The G272A mutation recently identi¢ed [13] within an
89Arg-X-Gly-Arg-93Arg motif, located in the ¢rst endofacial
loop of GLUT1 (Fig. 1) and highly conserved among
GLUT1^8, was shared by three a¡ected family members sug-
gesting pathogenicity. The in vivo mutation substituted gly-
cine, a conserved small, hydrophobic and neutral amino acid,
by aspartate, a long, hydrophilic and acidic, negatively
charged amino acid. In addition, site-directed mutagenesis
changed the glycine residue to alanine. Glycine within this
motif may be involved in maintaining a certain distance be-
tween helix 1 and 2 or may support a particular orientation of
the adjacent arginine residues crucial for full catalytic activity
of GLUT1. Recently the substitution of the three arginine
residues within the 89Arg-X-Gly-Arg-93Arg motif by glycine
resulted in a translocation of the cytoplasmic loop into the
exoplasm along with the two £anking transmembrane seg-
ments, thus completely abolishing GLUT1-mediated transport
in Xenopus oocytes [34].
Confocal laser microscopy and immunoblotting indicated
that the levels of the mutant transporters in plasma membrane
or the total membrane fraction were comparable with that of
wild-type GLUT1. In particular, analyses of the relative in-
tensity of the plasma membrane versus cytoplasm £uorescence
con¢rmed that both the wild-type and the mutant GLUT1
transporters are expressed on the cell surface.
In vitro functional analyses were performed in two di¡erent
cell systems. Two independent assays investigating zero-trans
3OMG uptake into erythrocytes showed impaired 3OMG
transport in patients (Fig. 3A^C). Vmax values of patients
and control are in agreement with previous reports [10,35].
No signi¢cant di¡erences in apparent Km were observed be-
tween patients and control (1.0^1.3 mmol/l), resembling the
apparent Km of 1.6 mmol/l reported in the literature for zero-
trans in£ux conditions similar to those utilised here [36]. In
Xenopus oocytes, both the G91D mutant, equivalent to the in
vivo mutation, and the G91A mutant showed impaired Vmax
values, con¢rming the data obtained in erythrocytes. This
supports the hypothesis that amino acid charges in the R-X-
G-R-R motif likely play no direct role in the transport, but
rather the particular amino acid and its position within the
conformational structure are crucial for transport or mem-
brane topology [34]. In contrast to the erythrocyte uptake
data, the apparent Km values were decreased in both mutants
if assessed in Xenopus oocytes. The kinetic data for wild-type
GLUT1 are in agreement with published results [36,37]. Ki-
netic analyses in di¡erent cell systems using substrates with
di¡erent transport kinetics might be responsible for the di-
verging results of Km values in Xenopus oocytes and erythro-
Fig. 3. Glucose transport into erythrocytes and Xenopus oocytes ex-
pressing wild-type GLUT1 and G91D or G91A mutant GLUT1
transporters. A: Zero-trans in£ux of 3OMG into erythrocytes over
30 s in patient II:5 and I:2. The data were expressed as the natural
logarithm of the ratio of intra-cellular radioactivity at time T and
at equilibrium versus time in seconds (four determinations/data-
point). The bars represent the means þ S.E.M. of relative uptake
rates. The relative uptake values from both patients and the control,
shown on the right y-axis, were compared to 70 controls as de-
scribed in [23]. B: Saturation kinetics of 3OMG zero-trans in£ux
into erythrocytes of patients and control as velocity (v) versus [S]
(0.3^6 mmol/l, four determinations/datapoint). C: The data shown
in (B) are presented as a double-reciprocal plot of 3OMG transport
velocity (v) in fmol s31 106RBC31 versus substrate concentration [S]
in mmol/l to determine kinetic parameters shown in Table 1.
D: Basal uptake rates of 2DOG into Xenopus oocytes. Xenopus oo-
cytes were injected with cRNAs encoding the 91GCD or 91GCA
mutant. The accumulation of tritium-labelled 2DOG (50 Wmol/l)
was assessed in single oocytes for 30 min. Each assay contained 10^
15 oocytes and a separate experiment included three independent as-
says per group. The means þ S.D. represent the relative uptake rates
from two independent experiments. The values of water-injected
Xenopus oocytes were always subtracted. The 2DOG uptake rates
by wild-type GLUT1 were 67.3 þ 20.1 pmol per oocyteU30 min31
(mean þ S.D.; n = 90 oocytes). E: Lineweaver^Burk plot. Kinetic
analysis was performed by using groups of 20^30 Xenopus oocytes
per datapoint to measure 2DOG uptake into oocytes expressing
wild-type GLUT1 or the 91GCD and 91GCA mutants. Five di¡er-
ent substrate concentrations were chosen to measure 2DOG in£ux
during 30 min (15 min at 25 mmol/l substrate concentration). The
values for water-injected Xenopus oocytes were always subtracted.
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cytes, however, further explanations at this point remain spec-
ulative. Analyses of further missense mutations identi¢ed in
GLUT1 De¢ciency Syndrome in both cell systems will be
helpful to address this issue.
In summary we report the functional analysis of the ¢rst
autosomal dominant mutation identi¢ed in GLUT1 De¢-
ciency Syndrome by expression in Xenopus oocytes, following
Mueckler’s report of a dysfunctional mutation in GLUT2
[30]. We conclude that the Gly91Asp mutation within a highly
conserved sequence of the GLUT1 gene highlights its impor-
tance for GLUT1 function. Since both the substitutions of
glycine-91 to either aspartate or alanine led to equally im-
paired 2-DOG uptake rates into Xenopus oocytes the loss of
glycine at this particular position rather than the introduction
of an acidic hydrophilic side chain (Gly91Asp) de¢nes the in
vivo functional consequences of this missense mutation in the
human GLUT1 gene. The data presented indicate that the
heterologous expression in Xenopus oocytes is a useful strat-
egy to investigate the functional consequences of in vivo mu-
tations in human GLUT genes. Further analyses of the func-
tional consequences of single-allele disruptions in the GLUT1
gene are necessary to unravel the genetic and biochemical
background of GLUT1 De¢ciency Syndrome.
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